Summary of Conference Call Notes Industry or Company Involved - Miniso (名创优品) - Top Toy - Yonghui Supermarket (永辉超市) - Baijiu Industry (白酒行业) - Express Delivery Industry (快递行业) - Weixing Precision (帏翔精密) - TCL Electronics (TCL 电子) - Aimeike (爱美客) Key Points and Arguments Miniso Performance and Strategy - Miniso achieved revenue of 400 million in 2024, a year-on-year increase of 23% and a net profit of 2.6 billion, up 16% [2] - The company opened 460 new stores in China, totaling 4,386 stores [2] - The SKU count increased to 12,600 with a monthly launch rate of 1,180 new products [2] - In overseas markets, particularly North America, 265 new stores were opened, with overseas GMV growth exceeding 50% and agency market growth at 17% [4] Top Toy Development - Top Toy opened 128 new stores last year, doubling its store count and achieving profitability with a pre-tax profit margin exceeding 9% [2][5] Yonghui Supermarket Acquisition - The acquisition of Yonghui Supermarket was completed in Q1, with expectations for it to break even this year, limiting its drag on Miniso [6] Baijiu Industry Trends - The baijiu industry is expected to see an upward turning point, with inventory decreasing year-on-year and improved demand during the Spring Festival [7] - High-end liquor demand remains stable, while mid-to-low price segments face challenges [7] Express Delivery Industry Insights - In early March, express delivery volume growth remained at 20%-21%, higher than expected [8] - A shift in the industry from peak to off-peak season is anticipated, with revenue growth expected to approach 15% [8] Weixing Precision Financials - Weixing Precision reported a net profit of 10.15 billion in 2024, a 12.7% year-on-year increase, meeting expectations [9] TCL Electronics Performance - TCL Electronics reported revenue of 99.32 billion HKD in 2024, a 25.7% increase, and a net profit of 1.61 billion HKD, up 100.1% [13] - The company expects a dividend payout ratio of 50% [13] - TV sales in China grew by 5.8%, while overseas sales increased by 17.6% [13] Aimeike's Financial Performance - Aimeike's revenue and net profit growth were approximately 5% in 2024, but Q4 saw a decline in revenue by 7% and net profit by 15% [17] - The company plans to focus on internal growth and external acquisitions, with several new products expected to launch in 2025 [18][20] Future Outlook for Aimeike - Aimeike's revenue and profit growth is projected to be around 11% in 2025, with potential acceleration in 2026 and 2027 due to new product launches and acquisitions [20] Other Important but Possibly Overlooked Content - The express delivery industry is facing a transition period, and companies like Zhongtong Express are setting ambitious growth targets of 20%-24% for parcel volume [10] - Yunda is under investigation by the National Postal Administration, which may affect its business relationships with major clients [11] - SF Express's strategic investment in Dekun Logistics aims to enhance cost efficiency through business collaboration [12] - TCL's other display and internet business segments showed steady growth, with significant contributions from innovative business areas [14][15]

Investment Rating - The report maintains a "Buy-B" rating for the company [1][8]. Core Views - The company has a rich pipeline of products under development and is accelerating its international expansion through acquisitions [1][7]. - The company reported a revenue of 3.026 billion yuan in 2024, representing a year-on-year growth of 5.45%, with a net profit of 1.958 billion yuan, also up by 5.33% [4][10]. - The company plans to distribute a cash dividend of 38 yuan per 10 shares, which accounts for 58.51% of the net profit attributable to shareholders [4]. Financial Performance - The company achieved a gross margin of 94.64%, a decrease of 0.46 percentage points, and a net margin of 64.66%, an increase of 0.01 percentage points [6]. - The operating cash flow for the period was 1.927 billion yuan, down by 1.38% [6]. - The company’s revenue from gel products was 1.216 billion yuan, up by 5.01%, with a gross margin of 97.98%, an increase of 0.49 percentage points [5]. Product Development and Market Expansion - The company has three products in the registration application stage and three in clinical trials, indicating a robust product pipeline [5][7]. - The acquisition of an 85% stake in the South Korean medical aesthetics company Regen Biotech for 190 million USD is expected to enhance the company's product offerings and accelerate its international presence [7]. Market Data - As of March 21, 2025, the company's closing price was 190.10 yuan, with a total market capitalization of 57.523 billion yuan [3]. - The company’s earnings per share (EPS) for 2024 was reported at 6.50 yuan [4]. Future Projections - The projected EPS for 2025, 2026, and 2027 are 7.06 yuan, 7.93 yuan, and 8.66 yuan respectively, with corresponding price-to-earnings (P/E) ratios of 26.9, 24.0, and 22.0 [7][10].

Investment Rating - The report maintains a "Buy-B" rating for the company [1][8]. Core Views - The company has a rich pipeline of products under development and is accelerating its international expansion through acquisitions [1][6]. - In 2024, the company achieved a revenue of 3.026 billion yuan, representing a year-on-year growth of 5.45%, and a net profit of 1.958 billion yuan, also up by 5.33% [2][4]. - The company plans to distribute a cash dividend of 38 yuan per 10 shares, which accounts for 58.51% of the net profit attributable to shareholders [2]. Financial Performance - The company reported a gross margin of 94.64%, a net margin of 64.66%, and an overall expense ratio of 22.21% for the period [4]. - The revenue from solution products was 1.744 billion yuan, with a gross margin of 93.76%, while gel products generated 1.216 billion yuan with a gross margin of 97.98% [3]. - The company has three products in the registration application stage and three in clinical trials, indicating a robust product pipeline [3][4]. Regional Performance - Revenue from different regions showed varied growth: North China +33.21%, Central China +19.84%, while East China saw a decline of -4.08% [3]. - Direct sales accounted for 66.37% of total sales, while distribution sales made up 33.63% [3]. Acquisition Strategy - The company plans to acquire 85% of the Korean medical beauty company Regen Biotech for 190 million USD, which will enhance its product line and accelerate internationalization [6]. - The target company reported a revenue of 72 million yuan and a net profit of 30 million yuan for the first nine months of 2024 [6]. Earnings Forecast - The projected EPS for 2025, 2026, and 2027 are 7.06 yuan, 7.93 yuan, and 8.66 yuan respectively, with corresponding P/E ratios of 26.9, 24.0, and 22.0 [6][10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a total revenue of 3.026 billion yuan in 2024, representing a year-on-year growth of 5.45%, and a net profit attributable to shareholders of 1.958 billion yuan, also up by 5.33% [8] - The company maintains a high level of profitability, with a gross margin of 94.64% and a net margin of 64.66% in 2024, despite a slight decrease in gross margin [8] - The company has a rich pipeline of products under research, which ensures long-term growth, and is accelerating its international business layout through acquisitions [8] Summary by Sections Financial Performance - In 2024, the company reported total revenue of 3.026 billion yuan, with a year-on-year increase of 5.45% [8] - The net profit attributable to shareholders was 1.958 billion yuan, reflecting a growth of 5.33% year-on-year [8] - The company’s earnings per share (EPS) for 2024 is projected at 6.47 yuan [9] Product and Market Strategy - The company’s solution and gel products continue to grow, with sales of the "Hi Body" series reaching 1.744 billion yuan, up 4.40% year-on-year, and the "Mo White Angel" series generating 1.216 billion yuan, up 5.01% [8] - The company has engaged in extensive academic activities and digital marketing to enhance brand influence and provide comprehensive solutions to medical institutions and consumers [8] Research and Development - The company has 11 Class III medical device products approved by the National Medical Products Administration and a rich pipeline of products under research, including botulinum toxin and other innovative treatments [8] - The planned acquisition of 85% of REGEN Biotech aims to expand the product pipeline and accelerate international business development [8] Profitability and Cost Management - The company’s sales, management, research and development, and financial expense ratios for 2024 were 10.93%, 4.82%, 17.88%, and -0.66% respectively, indicating an increase in sales expenses due to heightened marketing efforts [8] - The overall profitability remains high, with a slight decrease in gross margin for solution products but an increase for gel products [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a total revenue of 3.026 billion yuan in 2024, representing a year-on-year growth of 5.45%, and a net profit attributable to shareholders of 1.958 billion yuan, also up by 5.33% year-on-year [8] - The company maintains a high level of profitability, with a gross margin of 94.64% and a net margin of 64.66% in 2024, indicating stable profitability despite slight declines in gross margin [8] - The company has a rich pipeline of products under research and development, which is expected to support long-term growth, alongside an accelerated international business layout [8] Summary by Sections Financial Performance - In 2024, the company reported total revenue of 3.026 billion yuan, with a year-on-year increase of 5.45% [8] - The net profit attributable to shareholders was 1.958 billion yuan, reflecting a year-on-year growth of 5.33% [8] - The company’s earnings per share (EPS) for 2024 is projected at 6.47 yuan, with a price-to-earnings (P/E) ratio of 30.41 [1][9] Product and Market Strategy - The company’s solution and gel products continue to grow, with sales of the "Hi Body" series generating 1.744 billion yuan, up 4.40% year-on-year, and the "Mo White Angel" series achieving 1.216 billion yuan, up 5.01% year-on-year [8] - The company leverages academic activities and digital marketing to enhance brand influence and provide comprehensive solutions to medical institutions and consumers [8] Research and Development - The company has 11 Class III medical device products approved by the National Medical Products Administration, with a diverse pipeline including botulinum toxin and other innovative products [8] - A planned acquisition of 85% of South Korean REGEN Biotech is expected to enhance the product pipeline and accelerate international expansion [8] Profitability and Cost Management - The company’s sales, management, R&D, and financial expense ratios for 2024 are 10.93%, 4.82%, 17.88%, and -0.66% respectively, indicating an increase in sales expenses due to heightened marketing efforts [8] - The gross margin for solution products slightly decreased to 93.76%, while gel products saw an increase to 97.98% due to the growth of high-end products [8]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of 237.90 RMB [8][9]. Core Views - The company reported a revenue of 3.026 billion RMB for 2024, a year-on-year increase of 5.45%, and a net profit attributable to the parent company of 1.958 billion RMB, also up by 5.33% year-on-year. However, the Q4 2024 revenue was 650 million RMB, down 7% year-on-year, and net profit was 372 million RMB, down 15% year-on-year, which was below previous expectations due to pressure on the medical aesthetics sector [1]. - The acquisition of 85% of Korean Regen Company for 190 million USD (approximately 1.386 billion RMB) is expected to inject performance momentum and boost market confidence. This marks the company's first overseas acquisition since its listing [1][4]. - Short-term recovery in the medical aesthetics sector may provide room for performance and valuation recovery, while long-term global resource integration and pipeline expansion are anticipated to create new growth trajectories [1]. Revenue and Profit Forecast - The company’s revenue is projected to grow to 3.643 billion RMB in 2025, representing a 20.41% increase, and net profit is expected to reach 2.398 billion RMB, a 22.52% increase. The EPS for 2025 is estimated at 7.93 RMB [5][7]. - The company’s estimated PE for 2025 is 30 times, with a target price of 237.90 RMB based on this valuation [5]. Product Performance - The revenue from gel products reached 1.216 billion RMB, growing by 5.01% year-on-year, driven mainly by the launch of new products. The solution category generated 1.744 billion RMB, with a stable growth of 4.4% year-on-year [2]. Regional Expansion - The company has significant expansion potential in regions such as North China, Central China, and South China, with North China showing a revenue increase of 33.21% year-on-year [3].